|Rapid review complete
|For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that dupilumab (Dupixent®) not be considered for reimbursement at the submitted price*
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.